Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Cortellini A, et al. Among authors: gori s. Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30. Cancer Immunol Immunother. 2020. PMID: 32474768 Free PMC article.
Primary and metastatic brain tumors.
Franceschi E, Scopece L, Gori S, Chiari R, Crino L. Franceschi E, et al. Among authors: gori s. Forum (Genova). 2006;14(1):E2. Forum (Genova). 2006. PMID: 16873085
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Natoli C, et al. Among authors: gori s. J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20. J Cancer Res Clin Oncol. 2013. PMID: 23604446 Free PMC article.
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'.
Foglietta J, Metro G, Crinò L, Gori S. Foglietta J, et al. Among authors: gori s. Ann Oncol. 2015 May;26(5):1033-1034. doi: 10.1093/annonc/mdv040. Epub 2015 Jan 28. Ann Oncol. 2015. PMID: 25632067 Free article. No abstract available.
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. Gori S, et al. PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015. PLoS One. 2015. PMID: 26340098 Free PMC article.
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, Gori S, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L. Metro G, et al. Among authors: gori s. Expert Opin Pharmacother. 2015;16(17):2601-13. doi: 10.1517/14656566.2015.1094056. Epub 2015 Oct 6. Expert Opin Pharmacother. 2015. PMID: 26439599
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.
Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R. Del Re M, et al. Among authors: gori s. Oncotarget. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957. Oncotarget. 2017. PMID: 26799287 Free PMC article.
434 results